Mast Therapeutics, Inc.

Form 4 June 21, 2013

### FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

**OMB APPROVAL** 

burden hours per response...

subject to Section 16. Form 4 or Form 5 obligations

if no longer

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

C/O ARENA

Security

(Instr. 3)

(Print or Type Responses)

may continue.

See Instruction

1. Name and Address of Reporting Person \* LIEF JACK

2. Issuer Name and Ticker or Trading Symbol

Mast Therapeutics, Inc. [MSTX]

5. Relationship of Reporting Person(s) to

Issuer

(First) (Last)

(Middle)

3. Date of Earliest Transaction

(Check all applicable)

(Month/Day/Year)

06/19/2013

X\_ Director 10% Owner Officer (give title Other (specify below)

PHARMACEUTICALS, INC., 6166

(Street)

NANCY RIDGE DRIVE

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

SAN DIEGO, CA 92121

(State) (Zip) (City) 1. Title of 2. Transaction Date 2A. Deemed

3. 4. Securities (Month/Day/Year) Execution Date, if TransactionAcquired (A) or Code Disposed of (D) (Instr. 3, 4 and 5) (Month/Day/Year) (Instr. 8)

5. Amount of Securities Beneficially Owned (I) Following

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial Ownership (Instr. 4) (Instr. 4)

Reported (A) Transaction(s) or

(Instr. 3 and 4) Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Conversion 3. Transaction Date 3A. Deemed (Month/Day/Year) Execution Date, if

5. Number of Transaction Derivative

6. Date Exercisable and **Expiration Date** 

7. Title and Amount of 8 Underlying Securities

#### Edgar Filing: Mast Therapeutics, Inc. - Form 4

| Security (Instr. 3)         | or Exercise<br>Price of<br>Derivative<br>Security |            | any<br>(Month/Day/Year) | Code (Instr. 8 | Securitie<br>Acquired<br>or Dispos<br>(D)<br>(Instr. 3,<br>and 5) | l (A)<br>sed of | (Month/Day,         | /Year)             | ear) (Instr. 3 and 4) |                                     |
|-----------------------------|---------------------------------------------------|------------|-------------------------|----------------|-------------------------------------------------------------------|-----------------|---------------------|--------------------|-----------------------|-------------------------------------|
|                             |                                                   |            |                         | Code V         | / (A)                                                             | (D)             | Date<br>Exercisable | Expiration<br>Date | Title                 | Amount<br>or<br>Number<br>of Shares |
| Stock Option (Right to Buy) | \$ 0.5                                            | 06/19/2013 |                         | A              | 62,451                                                            |                 | <u>(1)</u>          | 06/19/2023         | Common<br>Stock       | 62,451                              |

## **Reporting Owners**

| Reporting Owner Name / Address                                                                | Relationships |           |         |       |  |  |
|-----------------------------------------------------------------------------------------------|---------------|-----------|---------|-------|--|--|
| •                                                                                             | Director      | 10% Owner | Officer | Other |  |  |
| LIEF JACK<br>C/O ARENA PHARMACEUTICALS, INC.<br>6166 NANCY RIDGE DRIVE<br>SAN DIEGO, CA 92121 | X             |           |         |       |  |  |

# **Signatures**

/s/ Patrick L. Keran, Attorney-in-Fact for Jack Lief 06/21/2013

\*\*Signature of Reporting Person Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option vests and becomes exercisable in 12 substantially equal monthly installments on each monthly anniversary of June 19, 2013, subject to the reporting person's continued service with the issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2